Clinical Trial Update: Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

View source ↗

Summary

Clinical trial evaluating circulating tumor DNA as an early biomarker to assess treatment response across multiple solid tumors; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colon Cancer
• Esophageal Cancer
• Head and Neck Cancer
• Lung Cancer
• Melanoma
• Prostate Cancer
• Sarcoma

Snippet

Sponsor: Washington University School of Medicine | Conditions: Healthy Volunteer, Prostate Cancer | Status: RECRUITING